Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE014 (NLD) (Dr. Moreau)
· consented 2022-07-23
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-04 (study day 121); relationship: N
moderate
assessed
2026-08-18
Grade 2 Anaemia — outcome: UNKNOWN; onset 2023-05-23 (study day 291); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-07-15 (study day 344); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-12-17 (study day 499); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-12-27 (study day 509); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.